What Are the Side Effects of King Kanine CBD Oil? - Mustaf Medical
Understanding Potential Side Effects of King Kanine CBD Oil
Introduction
You've just finished a long day of virtual meetings, the kids are asleep, but your mind keeps replaying the to‑do list. A friend mentioned that a drop of King Kanine CBD oil before bed helped them unwind without feeling groggy. Curious, you wonder whether the oil could interfere with your morning focus, digestion, or any other aspect of daily life. Scientific literature on cannabidiol (CBD) in humans is expanding, yet the profile of side effects-especially for products originally formulated for pets-remains nuanced. This article summarizes current evidence, explains how CBD works in the body, compares it with other delivery formats, and outlines safety considerations so you can interpret the data without commercial pressure.
Science and Mechanism
Absorption and Bioavailability
When CBD is taken orally, it first passes through the stomach and then the small intestine, where it is absorbed into the portal circulation. Oral bioavailability is relatively low, typically ranging from 6 % to 19 % (Hložek et al., 2022, PubMed). The low figure reflects extensive first‑pass metabolism by cytochrome P450 enzymes (CYP3A4 and CYP2C19) in the liver, which convert CBD into hydroxylated metabolites such as 7‑hydroxy‑CBD. Lipid‑based formulations, like the carrier oils used in King Kanine products, modestly improve absorption by enhancing solubility of the lipophilic molecule.
Endocannabinoid System Interaction
CBD does not bind strongly to cannabinoid receptors CB1 and CB2. Instead, it acts as a negative allosteric modulator of CB1 and influences the activity of several non‑cannabinoid targets: TRPV1 (transient receptor potential vanilloid 1) channels, 5‑HT1A serotonin receptors, and PPARγ nuclear receptors. These interactions underlie many of the hypothesized therapeutic actions-anxiolysis, analgesia, and anti‑inflammatory effects-but they also create pathways for side effects. For example, activation of TRPV1 can produce a mild warming sensation, while modulation of 5‑HT1A may lead to transient dizziness in susceptible individuals.
Dose‑Response Relationships
Clinical trials on humans have typically examined doses between 10 mg and 100 mg of CBD per day. A 2023 randomized controlled trial (Rosenberg et al., Mayo Clinic Proceedings) found that doses up to 40 mg were well‑tolerated, with adverse events reported in fewer than 15 % of participants. Higher doses (≥ 70 mg) showed a modest increase in reports of gastrointestinal discomfort and somnolence. Because King Kanine's oil is labeled for pets, the human‑equivalent dosing is not standardized; users often extrapolate from the "drop" guidelines, which may translate to 5 mg–15 mg per drop depending on the concentration.
Pharmacokinetic Variability
Age, body mass index, liver function, and concurrent medications significantly influence CBD plasma levels. Studies indicate that a 70‑kg adult with normal hepatic function reaches peak concentration (C_max) approximately 2–3 hours after oral ingestion, whereas elderly participants may experience delayed clearance, extending the half‑life from 24 hours to upward of 48 hours (WHO, 2022). These pharmacokinetic nuances explain why some people notice side effects after a single dose while others report none even after chronic use.
Emerging Evidence vs. Established Findings
Robust evidence supports mild elevations in liver enzymes (ALT, AST) at doses ≥ 150 mg/day, particularly when combined with other hepatically metabolized drugs. Conversely, the link between low‑to‑moderate doses and serious adverse events remains weak. Ongoing investigations (NIH ClinicalTrials.gov identifier NCT0553247) are exploring long‑term safety in populations over 65, but results are pending.
Comparative Context
| Source/Form | Absorption/Metabolic Impact | Intake Ranges Studied | Limitations | Populations Studied |
|---|---|---|---|---|
| Full‑spectrum CBD oil (e.g., King Kanine) | Lipid‑based oral delivery; modestly higher bioavailability than aqueous solutions; interacts with CYP enzymes | 5 – 30 mg per day (typical pet guideline extrapolation) | Not standardized for humans; cannabinoid entourage may introduce variability | Adults 18‑55, limited data on seniors |
| CBD isolate (powder) | Pure CBD; oral capsules show 6‑12 % bioavailability; minimal entourage effect | 10 – 100 mg per day | Lack of additional terpenes may affect perception of side effects | Clinical trial participants with anxiety |
| CBD gummies (cbd gummies product for humans) | Gelatin matrix slows gastric emptying, leading to delayed C_max (3‑4 h); similar bioavailability to oil | 25 – 75 mg per day | Sugar content; batch‑to‑batch consistency varies | Young adults, recreational users |
| Hemp seed oil (natural source) | No CBD; contains trace cannabinoids; primarily omega‑3/6 fatty acids; negligible metabolic interaction | ≤ 1 g per day (nutritional) | Does not deliver pharmacologically active CBD | General population, dietary studies |
Population Trade‑offs
Adults 18‑55
Research consistently shows that this age group tolerates doses up to 40 mg/day of full‑spectrum oil with minimal side effects. The presence of minor cannabinoids (CBC, CBG) can modulate the metabolism of CBD, sometimes reducing liver enzyme elevations.
Older Adults (≥ 65)
Reduced hepatic clearance may prolong exposure, raising the likelihood of transient dizziness or fatigue. Guideline‑level caution advises starting at the lowest possible dose (e.g., 5 mg) and monitoring liver function quarterly.
Individuals on Polypharmacy Regimens
Because CBD is a CYP3A4 substrate, concomitant use with anticoagulants (warfarin), antiepileptics (clobazam), or certain antidepressants (SSRIs) can alter drug levels. Clinical case series have documented increased plasma concentrations of these agents, prompting recommendations for dosage adjustments under physician supervision.
Background
King Kanine CBD oil was originally formulated for canine wellness, leveraging hemp‑derived cannabidiol to address anxiety and joint discomfort in dogs. The product contains full‑spectrum cannabinoids, terpenes, and a carrier oil (often MCT or hemp seed oil). When humans consume the oil, the same phytochemical profile applies, but the dosing framework differs. "Side effects" in this context refer to any undesirable physiological response that occurs at typical consumer‑grade concentrations (generally ≤ 30 mg CBD per day). Reported effects span mild (dry mouth, light‑headedness) to more clinically relevant (elevated liver enzymes, drug‑interaction warnings). Because the oil is not regulated as a pharmaceutical, labeling may lack precise concentration data, making systematic assessment challenging.
Scientific interest in CBD for humans surged after the 2018 U.S. Farm Bill legalized hemp‑derived cannabinoids containing ≤ 0.3 % Δ⁹‑THC. Since then, over 250 clinical trials have been registered, many focusing on seizure disorders, chronic pain, and anxiety. However, few have examined pet‑formulated products directly, leaving a gap that systematic reviews attempt to bridge by aggregating adverse‑event data from broader CBD research.
Safety
Commonly Reported Side Effects
- Dry Mouth (Xerostomia): Frequently observed within 30 minutes of ingestion; thought to result from CB1 modulation of salivary glands.
- Drowsiness or Fatigue: Reported in 5 %–12 % of participants, especially at doses ≥ 50 mg. May be more pronounced when taken on an empty stomach.
- Gastrointestinal Discomfort: Mild nausea, diarrhea, or abdominal cramping appear in up to 8 % of users; typically resolves with dose reduction or food intake.
- Changes in Appetite: Some individuals note short‑term increases or decreases in hunger, likely mediated via endocannabinoid pathways.
Populations Requiring Caution
- Pregnant or Breastfeeding Individuals: Animal studies suggest potential fetal exposure; human data are insufficient, prompting conservative recommendations to avoid use.
- People with Hepatic Impairment: Reduced metabolic capacity heightens risk of enzyme elevation; liver function tests recommended before initiating therapy.
- Patients on Anticoagulants or Antiepileptics: Potential for pharmacokinetic interaction warrants clinician oversight.
Theoretical Interactions
CBD can inhibit CYP2C19 and CYP3A4, possibly increasing plasma concentrations of medications metabolized by these enzymes. While most interaction reports involve prescription drugs, OTC substances such as St. John's wort or grapefruit juice may also compound the effect. The magnitude of interaction is dose‑dependent and may be negligible at ≤ 10 mg but clinically relevant at higher daily intakes.
Guidance for Professional Consultation
Given the variability in individual metabolism, underlying health conditions, and concurrent medication use, a baseline health assessment-including liver enzymes (ALT, AST), renal function, and a medication review-is advisable prior to regular CBD consumption. Follow‑up testing after 4–6 weeks can detect any emergent changes.
FAQ
Can CBD cause drowsiness?
Yes, mild sedation is among the most frequently documented side effects, especially at doses above 50 mg per day or when taken shortly before bedtime. The effect is believed to stem from CBD's modulation of serotonin 5‑HT1A receptors and its indirect influence on the endocannabinoid system, but most users report only transient feelings of tiredness that resolve with continued use or dosage adjustment.
Is it safe to combine CBD with alcohol?
Current evidence suggests that CBD does not significantly amplify alcohol's intoxicating effects, but both substances share metabolic pathways in the liver. Concurrent use may increase liver enzyme activity, potentially stressing hepatic function in heavy drinkers. Moderation and medical guidance are recommended, particularly for individuals with pre‑existing liver disease.
What are the most common side effects reported?
The literature consistently highlights dry mouth, drowsiness, gastrointestinal upset, and appetite changes. Across randomized trials, each of these occurs in less than 15 % of participants, and most are classified as mild to moderate intensity. Serious adverse events are rare and usually linked to high‑dose regimens (> 150 mg/day) or drug interactions.
Do side effects differ between humans and dogs?
Species‑specific metabolism leads to different pharmacokinetic profiles. Dogs metabolize CBD more rapidly, often requiring higher per‑kilogram doses to achieve comparable plasma concentrations. Reported side effects in dogs include lethargy and lowered blood pressure, whereas humans more commonly experience dry mouth and mild gastrointestinal symptoms. Direct extrapolation of safety data between species is therefore not advisable.
How quickly do side effects appear after taking CBD?
Acute side effects such as dry mouth or light‑headedness can arise within 30 minutes to 2 hours following oral ingestion, coinciding with peak plasma levels (C_max). Longer‑term effects, like liver enzyme elevation, typically become apparent only after weeks of consistent daily dosing and are detected through laboratory testing rather than symptomatic presentation.
Disclaimer
This content is for informational purposes only. Always consult a healthcare professional before starting any supplement.